Literature DB >> 29525896

Radiation dose rates of differentiated thyroid cancer patients after 131I therapy.

Pingyan Jin1, Huijuan Feng2, Wei Ouyang3, Juqing Wu2, Pan Chen2, Jing Wang2, Yungang Sun2, Jialang Xian2, Liuhua Huang2.   

Abstract

Postoperative 131I treatment for differentiated thyroid cancer (DTC) can create a radiation hazard for nearby persons. The present prospective study aimed to investigate radiation dose rates in 131I-treated DTC patients to provide references for radiation protection. A total of 141 131I-treated DTC patients were enrolled, and grouped into a singular treatment (ST) group and a repeated treatment (RT) group. The radiation dose rate of 131I-treated patients was measured. The rate of achieving discharge compliance and restricted contact time were analyzed based on Chinese regulations. Multivariate logistic regression analysis was used to analyze the independent factors associated with the clearance of radioiodine. The rate of achieving discharge compliance (131I retention < 400 MBq) was 79.8 and 93.7% at day 2 (D2) for the ST and RT groups, respectively, and reached 100% at D7 and D4, respectively. The restricted contact time with 131I-treated patients at 0.5 m for medical staff, caregivers, family members, and the general public ranged from 4 to 7 days. Multivariate logistic regression analysis showed that the 24-h iodine uptake rate was the only significant factor associated with radioiodine clearance. For the radiation safety of 131I-treated DTC patients, the present results can provide radiometric data for radiation protection.

Entities:  

Keywords:  131I treatment; Contact time restrictions; Differentiated thyroid cancer (DTC); Radiation safety; Radioiodine clearance

Mesh:

Substances:

Year:  2018        PMID: 29525896     DOI: 10.1007/s00411-018-0736-7

Source DB:  PubMed          Journal:  Radiat Environ Biophys        ISSN: 0301-634X            Impact factor:   1.925


  19 in total

1.  The SNMMI practice guideline for therapy of thyroid disease with 131I 3.0.

Authors:  Edward B Silberstein; Abass Alavi; Helena R Balon; Susan E M Clarke; Chaitanya Divgi; Michael J Gelfand; Stanley J Goldsmith; Hossein Jadvar; Carol S Marcus; William H Martin; J Anthony Parker; Henry D Royal; Salil D Sarkar; Michael Stabin; Alan D Waxman
Journal:  J Nucl Med       Date:  2012-07-11       Impact factor: 10.057

2.  Estimating risk of recurrence in differentiated thyroid cancer after total thyroidectomy and radioactive iodine remnant ablation: using response to therapy variables to modify the initial risk estimates predicted by the new American Thyroid Association staging system.

Authors:  R Michael Tuttle; Hernan Tala; Jatin Shah; Rebecca Leboeuf; Ronald Ghossein; Mithat Gonen; Matvey Brokhin; Gal Omry; James A Fagin; Ashok Shaha
Journal:  Thyroid       Date:  2010-10-29       Impact factor: 6.568

3.  131I effective half-life (Teff) for patients with thyroid cancer.

Authors:  J Willegaignon; Luiz F Malvestiti; Maria I C Guimarães; Marcelo T Sapienza; Irene S Endo; Guilherme C Neto; Marília Marone; Gian-Maria A A Sordi
Journal:  Health Phys       Date:  2006-08       Impact factor: 1.316

4.  Estimation of external radiation dose to caregivers of patients treated with radioiodine after thyroidectomy.

Authors:  Kyu Hwan Jeong; Jae Won Jung; Chang Bum Kim; Byeong-Cheol Ahn; Hyun Kuk Lee; Song Jae Yoo; Orville Day; Jai Ki Lee
Journal:  Health Phys       Date:  2014-04       Impact factor: 1.316

5.  The evaluation of urine activity and external dose rate from patients receiving radioiodine therapy for thyroid cancer.

Authors:  Mustafa Demir; Yasemin Parlak; Iffet Cavdar; Nami Yeyin; Handan Tanyildizi; Gül Gümüser; Elvan Sayit; Serap Erees; Haluk Sayman
Journal:  Radiat Prot Dosimetry       Date:  2013-03-27       Impact factor: 0.972

6.  A retrospective study on the transition of radiation dose rate and iodine distribution in patients with I-131-treated well-differentiated thyroid cancer to improve bed control shorten isolation periods.

Authors:  Naoya Yama; Koh-ichi Sakata; Hideki Hyodoh; Mitsuharu Tamakawa; Masato Hareyama
Journal:  Ann Nucl Med       Date:  2012-03-03       Impact factor: 2.668

7.  Correlation Between Exposure Rate and Residual Activity in Felines Undergoing 131I Thyroid Ablation Therapy.

Authors:  T Michael Martin; Latha Vasudevan; Sunil S Chirayath
Journal:  Health Phys       Date:  2015-08       Impact factor: 1.316

8.  Estimation of close contact doses to young infants from surface dose rates on radioactive adults.

Authors:  P J Mountford
Journal:  Nucl Med Commun       Date:  1987-11       Impact factor: 1.690

9.  Could the treatment of differentiated thyroid carcinoma with 3.7 and 5.55 GBq of (131I)NaI, on an outpatient basis, be safe?

Authors:  José Willegaignon de Amorim de Carvalho; Marcelo Sapienza; Carla Ono; Tomoco Watanabe; Maria Inês Guimarães; Ricardo Gutterres; Maria Helena Marechal; Carlos Buchpiguel
Journal:  Nucl Med Commun       Date:  2009-07       Impact factor: 1.690

Review 10.  Molecular pathology of differentiated thyroid cancer.

Authors:  A Greco; M G Borrello; C Miranda; D Degl'Innocenti; M A Pierotti
Journal:  Q J Nucl Med Mol Imaging       Date:  2009-10       Impact factor: 2.346

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.